MA40880A - Éradication guidée par l'arn du virus jc humain et d'autres polyomavirus - Google Patents

Éradication guidée par l'arn du virus jc humain et d'autres polyomavirus

Info

Publication number
MA40880A
MA40880A MA040880A MA40880A MA40880A MA 40880 A MA40880 A MA 40880A MA 040880 A MA040880 A MA 040880A MA 40880 A MA40880 A MA 40880A MA 40880 A MA40880 A MA 40880A
Authority
MA
Morocco
Prior art keywords
polyomaviruses
eradication
rna
virus
guided
Prior art date
Application number
MA040880A
Other languages
English (en)
Inventor
Wenhui Hu
Kamel Khalili
Hassen Wollebo
Original Assignee
Temple Univ Of The Commonwealth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple Univ Of The Commonwealth filed Critical Temple Univ Of The Commonwealth
Publication of MA40880A publication Critical patent/MA40880A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
MA040880A 2014-10-30 2015-10-29 Éradication guidée par l'arn du virus jc humain et d'autres polyomavirus MA40880A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462072927P 2014-10-30 2014-10-30
US201562169390P 2015-06-01 2015-06-01
US201562169638P 2015-06-02 2015-06-02

Publications (1)

Publication Number Publication Date
MA40880A true MA40880A (fr) 2017-09-05

Family

ID=55858408

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040880A MA40880A (fr) 2014-10-30 2015-10-29 Éradication guidée par l'arn du virus jc humain et d'autres polyomavirus

Country Status (11)

Country Link
US (2) US20170333572A1 (fr)
EP (1) EP3212795A4 (fr)
CN (2) CN107406854B (fr)
AU (1) AU2015338993B2 (fr)
CA (1) CA2967990C (fr)
HK (1) HK1247636A1 (fr)
MA (1) MA40880A (fr)
MX (1) MX2017005672A (fr)
RU (1) RU2747722C2 (fr)
WO (1) WO2016070070A1 (fr)
ZA (1) ZA201703163B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9068179B1 (en) 2013-12-12 2015-06-30 President And Fellows Of Harvard College Methods for correcting presenilin point mutations
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
IL258821B (en) 2015-10-23 2022-07-01 Harvard College Nucleobase editors and their uses
JP2019508364A (ja) * 2015-12-09 2019-03-28 エクシジョン バイオセラピューティクス インコーポレイテッド 免疫抑制療法中のｊｃウイルス活性化およびｐｍｌ（進行性多巣性白質脳症）のリスクを除去するための遺伝子編集方法および組成物
JP2019512458A (ja) * 2016-01-25 2019-05-16 エクシジョン バイオセラピューティクス インコーポレイテッド Ｒｎａによって誘導された、ヒトｊｃウイルス及び他のポリオーマウイルスの根絶
US20190161743A1 (en) * 2016-05-09 2019-05-30 President And Fellows Of Harvard College Self-Targeting Guide RNAs in CRISPR System
AU2017273713A1 (en) * 2016-06-01 2018-10-25 Excision Biotherapeutics, Inc. Compositions and methods of treatment for lytic and lysogenic viruses
WO2018017754A1 (fr) * 2016-07-19 2018-01-25 Duke University Applications thérapeutiques de l'édition du génome fondée sur cpf1
KR102547316B1 (ko) 2016-08-03 2023-06-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
CN109804066A (zh) 2016-08-09 2019-05-24 哈佛大学的校长及成员们 可编程cas9-重组酶融合蛋白及其用途
WO2018039438A1 (fr) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation d'acides aminés non naturels dans des protéines au moyen de l'édition de bases
KR102622411B1 (ko) 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
WO2018119359A1 (fr) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Édition du gène récepteur ccr5 pour protéger contre l'infection par le vih
WO2018165504A1 (fr) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression de la douleur par édition de gène
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
GB2575930A (en) 2017-03-23 2020-01-29 Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
EP3676376A2 (fr) 2017-08-30 2020-07-08 President and Fellows of Harvard College Éditeurs de bases à haut rendement comprenant une gam
WO2019079347A1 (fr) 2017-10-16 2019-04-25 The Broad Institute, Inc. Utilisations d'éditeurs de bases adénosine
WO2020191249A1 (fr) 2019-03-19 2020-09-24 The Broad Institute, Inc. Procédés et compositions pour l'édition de séquences nucléotidiques
WO2021096912A2 (fr) * 2019-11-11 2021-05-20 Temple University - Of The Commonwealth System Of Higher Education Système crispr/cas9 en tant qu'agent d'inhibition d'une infection par le polyome jc
MX2022014008A (es) 2020-05-08 2023-02-09 Broad Inst Inc Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo.
CN112322587A (zh) * 2020-09-17 2021-02-05 杭州市第一人民医院 一种带Cas9基因的人源可诱导多能干细胞系、构建方法、鉴定方法及应用
RU2747820C1 (ru) * 2020-11-30 2021-05-14 Федеральное бюджетное учреждение науки «Центральный научно-исследовательский институт эпидемиологии» Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ЦНИИ Эпидемиологии Роспотребнадзора) Система CRISPR-Cas для выявления ДНК вируса Джона Каннингема (JCPyV) в ультранизких концентрациях
RU2747819C1 (ru) * 2020-11-30 2021-05-14 Федеральное бюджетное учреждение науки «Центральный научно-исследовательский институт эпидемиологии» Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ЦНИИ Эпидемиологии Роспотребнадзора) Способ получения препарата рибонуклеопротеинового комплекса CRISPR/Cas и препарат для выявления ДНК вируса Джона Каннингема (JCPyV) в ультранизких концентрациях

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054312A (en) * 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
WO2007127919A2 (fr) * 2006-04-28 2007-11-08 Alnylam Pharmaceuticals, Inc. Compositions et procédés d'inhibition de l'expression d'un gène du virus jc
US10544405B2 (en) * 2013-01-16 2020-01-28 Emory University Cas9-nucleic acid complexes and uses related thereto

Also Published As

Publication number Publication date
EP3212795A1 (fr) 2017-09-06
CA2967990A1 (fr) 2016-05-06
RU2017115838A (ru) 2018-11-30
MX2017005672A (es) 2018-11-09
CN107406854A (zh) 2017-11-28
EP3212795A4 (fr) 2018-06-27
CN107406854B (zh) 2022-03-11
WO2016070070A1 (fr) 2016-05-06
RU2747722C2 (ru) 2021-05-13
CN115044570A (zh) 2022-09-13
US20230001016A1 (en) 2023-01-05
ZA201703163B (en) 2019-03-27
AU2015338993B2 (en) 2021-12-09
AU2015338993A1 (en) 2017-05-25
CA2967990C (fr) 2024-02-13
RU2017115838A3 (fr) 2018-11-30
HK1247636A1 (zh) 2018-09-28
US20170333572A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
MA40880A (fr) Éradication guidée par l'arn du virus jc humain et d'autres polyomavirus
EP3408392A4 (fr) Éradication du virus jc humain et d'autres polyomavirus guidée par un arn
MA50813A (fr) Vaccins contre le virus d'epstein-barr
EP3349783C0 (fr) Compositions et méthodes associées au traitement de maladies
IL244431A0 (en) Pharmacy methods and preparations for the treatment of hepatitis b virus infection
ZA201803978B (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
EP3309251A4 (fr) Vecteur viral de parainfluenza de type 2 humain et vaccin
IL256515A (en) Therapeutic peptides and methods of use thereof
EP3220953A4 (fr) Compositions et procédés d'utilisation de peptides thérapeutiques en relation avec p53 et de leurs analogues
SG11201701256RA (en) Vaccine compositions against dengue virus diseases
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
EP3419638A4 (fr) Compositions et procédés de traitement de maladies infectieuses chroniques
SG11201510266SA (en) Dengue virus vaccine compositions and methods of use thereof
SG11201704942QA (en) Dengue virus vaccine compositions and methods of use thereof
HK1205147A1 (en) Truncated l1 proteins of human papillomavirus type 45 45 l1
EP3265108A4 (fr) Peptides et compositions les comprenant, et utilisations de ces derniers dans le traitement de maladies
RS64461B1 (sr) Farmaceutske formulacije pegilovanih lipozoma i faktora koagulacije krvi
GB201421888D0 (en) Peptides derived from mysoin 19 and methods of use thereof
ZA201805989B (en) Compositions and methods of treatment of chronic infectious diseases
GB201516303D0 (en) Compositions and methods relating to the treatment of diseases
GB201516437D0 (en) Compositions and methods relating to the treatment of disease
TH1501007357A (th) โครงสร้างเนื้อเยื่อและวิธีการเตรียมของมัน